News
18h
Stocktwits on MSNFibrogen Gets Regulator’s Green Light To Sell China Unit To AstraZeneca
FibroGen, Inc. (FGEN) on Monday said that a Chinese regulator has approved the sale of its unit FibroGen International (Hong ...
Sale of FibroGen China remains on track to close in 3Q 2025 SAN FRANCISCO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the China State Administration for ...
18h
TipRanks on MSNFibroGen announces approval for FibroGen China sale to AstraZeneca
FibroGen (FGEN) announced that the China State Administration for Market Regulation approved the sale of FibroGen International to AstraZeneca ...
Total consideration for the sale of FibroGen China to AstraZeneca now expected to be approximately $210 million, a $50 million increase from initial guidance Net cash held in China at closing now ...
Analysts anticipate FibroGen to report an earnings per share (EPS) of $-0.30. Investors in FibroGen are eagerly awaiting the ...
FibroGen plans to file up to two INDs: FG-3165 (1Q 2024) and FG-3163 (4Q 2023). Additionally, the company expects to initiate a Phase 2 trial of FG-3246, targeting metastatic castration-resistant ...
FibroGen’s actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties related to the continued progress and timing of its ...
FibroGen shares are moving higher in Monday's after-hours session after the company announced the FDA cleared its Investigational New Drug (IND) FG-3165. The company also announced a new clinical ...
Last month, we discussed that FibroGen (NASDAQ: FGEN) stock price could rebound over a one-month period after falling 6% in a week, based on the Trefis Machine Learning Engine. However, FGEN stock ...
The stock price of FibroGen (NASDAQ: FGEN), a biopharmaceutical company focused on therapeutics in immunology and oncology, reached its 52-week high of $56 in February this year before a larger ...
FibroGen was evaluating the DMD therapy, pamrevlumab, in a late-stage trial in patients with non-ambulatory forms of the disorder, versus a placebo.
FibroGen, inc (FGEN 7.31%) Q2 2021 Earnings Call Aug 9, 2021, 5:00 p.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Good day, and thank you for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results